%0 Journal Article
%T Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
%A Hai-Tao Zhang
%A Shen-Cun Fang
%A Wei-Ping Xie
%A Wen Huang
%A Ying-Ming Zhang
%J Archive of "OncoTargets and therapy".
%D 2019
%R 10.2147/OTT.S189984
%X Hypertension (HTN) is a common adverse event of the vascular endothelial growth factor pathway inhibitor apatinib. This study was conducted to evaluate the association of apatinib-induced HTN with clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC)
%K biomarker
%K hypertension
%K apatinib
%K non-small-cell lung cancer
%K clinical outcomes
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362948/